IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study
Wang, Yu1; Liu, Qi-Fa2; Xu, Lan-Ping1; Liu, Kai-Yan1; Zhang, Xiao-Hui1; Ma, Xiao3; Fan, Zhi-Ping2; Wu, De-Pei3; Huang, Xiao-Jun1,4
刊名BLOOD
2015-06-18
DOI10.1182/blood-2015-02-627786
125期:25页:3956-3962
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
关键词[WOS]STEM-CELL TRANSPLANTATION ; ACUTE MYELOID-LEUKEMIA ; 1ST COMPLETE REMISSION ; ACUTE MYELOGENOUS LEUKEMIA ; DONOR LYMPHOCYTE INFUSION ; BONE-MARROW TRANSPLANT ; RISK ACUTE-LEUKEMIA ; HEMATOPOIETIC TRANSPLANTATION ; UNRELATED DONOR ; MYCOPHENOLATE-MOFETIL
英文摘要

The effects of HLA-identical sibling donor (ISD) hematopoietic stem cell transplantation (HSCT) on adults with intermediate-or high-risk acute myeloid leukemia (AML) in the first complete remission (CR1) are well established. Previous single-center studies have demonstrated similar survival after unmanipulated haploidentical donor (HID) vs ISD HSCT for hematologic malignancies. To test the hypothesis that haploidentical HSCT would be a valid option as postremission therapy for AML patients in CR1 lacking a matched donor, we designed a disease-specific, prospective, multi-center study. Between July 2010 and November 2013, 450 patients were assigned to undergo HID (231 patients) or ISD HSCT (219 patients) according to donor availability. Among HID and ISD recipients, the 3-year disease-free survival rate was 74% and 78% (P=.34), respectively; the overall survival rate was 79% and 82%(P=.36), respectively; cumulative incidences of relapse were 15% and 15% (P = .98); and those of the nonrelapse-mortality were 13% and 8% (P = .13), respectively. In conclusion, unmanipulated haploidentical HSCT achieves outcomes similar to those of ISD HSCT for AML patients in CR1. Such transplantation was demonstrated to be a valid alternative as postremission treatment of intermediate or high-risk AML patients in CR1 lacking an identical donor.

语种英语
WOS记录号WOS:000357283300018
项目编号81230013 ; 81400143 ; 2011-4022-08
资助机构Collaborative Innovation Center of Hematology China ; Key Program of National Natural Science Foundation of China ; National Natural Science Foundation of China ; Scientific Research Foundation for Capital Medicine Development
引用统计
被引频次:87[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50915
专题北京大学第二临床医学院_血液科
作者单位1.Soochow Univ, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China
2.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
3.Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
4.Peking Univ, Inst Hematol, Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Wang, Yu,Liu, Qi-Fa,Xu, Lan-Ping,et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study[J]. BLOOD,2015,125(25):3956-3962.
APA Wang, Yu.,Liu, Qi-Fa.,Xu, Lan-Ping.,Liu, Kai-Yan.,Zhang, Xiao-Hui.,...&Huang, Xiao-Jun.(2015).Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.BLOOD,125(25),3956-3962.
MLA Wang, Yu,et al."Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study".BLOOD 125.25(2015):3956-3962.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Yu]的文章
[Liu, Qi-Fa]的文章
[Xu, Lan-Ping]的文章
百度学术
百度学术中相似的文章
[Wang, Yu]的文章
[Liu, Qi-Fa]的文章
[Xu, Lan-Ping]的文章
必应学术
必应学术中相似的文章
[Wang, Yu]的文章
[Liu, Qi-Fa]的文章
[Xu, Lan-Ping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。